|
Neonatal Intensive Care Drug Manual
|
| bet | 20/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Adenosine
Revision Date: 15/12/2020
|
Approved : TC, KOH
|
Alert
|
Adenosine is used for pharmacological conversion of supraventricular tachycardia (SVT) to sinus rhythm. It is not a maintenance antiarrhythmic agent. Infants with SVT associated with serious cardiovascular compromise such as severe hypotension and decompensated heart failure should be converted with synchronised electrical cardioversion rather than adenosine.
|
Indication
|
Pharmacological conversion of supraventricular tachycardia. [1, 2]
|
Action
|
Endogenous purine analogue with rapid onset antiarrhythmic action resulting in transient AV nodal block. It has a short half-life (1–10 seconds). [3]
|
Drug Type
|
Antiarrhythmic
|
Trade Name
|
Adenocor, Aspen Adenosine
|
Presentation
|
6 mg/2 mL injection
|
|
|
| |
